Blood Pressure Pills That May Also Prevent Migraines: What a New Meta-Analysis Found About ARBs

For decades, neurologists managing migraine prevention have drawn from a familiar shortlist of drug classes: beta-blockers, antidepressants, anticonvulsants, and — more recently — CGRP-targeting biologics. Blood pressure medications from the angiotensin receptor blocker (ARB) family have hovered at the edges of that list, intriguing researchers but never quite earning a firm spot in major international treatment guidelines. The sticking point has always been the same: not enough high-quality evidence.

A new systematic review and meta-analysis, registered prospectively in the international PROSPERO database (CRD42023405372) and published in 2025, set out to change that. By pooling data from every controlled trial available — spanning database records from inception through September 2025 — the researchers assembled what is now the most comprehensive quantitative picture of how ARBs perform against migraine. Their findings suggest these drugs are more effective than current guidelines might imply, and that the field may have been undervaluing a readily available, generally well-tolerated treatment option.

What Are ARBs — and Why Would They Matter for Migraine?

Angiotensin receptor blockers were developed primarily to treat high blood pressure and heart disease. They work by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict. By preventing that constriction, ARBs relax blood vessels and lower blood pressure.

The connection to migraine is less obvious but not entirely surprising. The renin-angiotensin system — the hormonal pathway that ARBs target — is now understood to play a role in pain processing and vascular regulation within the brain. Migraine itself is a complex neurological disorder with a significant vascular component, meaning blood vessel behavior in and around the brain is central to how attacks unfold. The idea that a drug modulating that vascular behavior might reduce attack frequency has biological plausibility.

The ARB most studied for this purpose is candesartan, which has been examined in small individual trials over the past two decades with generally positive but inconsistently sized results. Because no single trial was large enough to be definitive, candesartan and its drug class have remained in a kind of clinical limbo — used by some specialists in practice but absent from the first-line recommendations of major guidelines. The meta-analysis aimed to resolve that ambiguity by treating all available trial data as a single, larger dataset.

How the Review Was Conducted

The researchers conducted a systematic search across seven major medical databases and registries — PubMed/MEDLINE, Embase, Cochrane, Google Scholar, ClinicalTrials.gov, ITCRP, and EudraCT — covering all records from their inception through September 22, 2025. The searches were performed across a four-day window between September 19 and 22, 2025, following a pre-registered protocol.

Eligibility criteria were deliberately rigorous. Only controlled trials comparing an ARB to either a placebo or another established migraine prevention drug were included. Participants had to carry a diagnosis of either episodic or chronic migraine. Publications such as guidelines, opinion letters, narrative reviews, editorials, and case reports were excluded. Two independent reviewers extracted data from qualifying studies, and the team used a random-effects model for the statistical pooling — a method that accounts for natural variation between studies rather than assuming all trials are measuring the exact same effect in the exact same population.

Heterogeneity — the statistical term for how much study results differ from each other — was measured using the Cochrane I² statistic. Risk of bias was evaluated using the Cochrane RoB2 tool, a structured framework for assessing whether individual trials were designed and conducted in ways that could have skewed their results. The certainty of the combined evidence was graded using GRADEpro, a globally recognized system for rating how much confidence researchers and clinicians can place in a body of findings.

Primary outcomes were monthly headache days, monthly migraine days, and 'responder rates' — defined as the proportion of participants who achieved at least a 50% reduction in migraine days. Adverse events were tracked as a secondary outcome.

Four Trials, 659 Participants, Two Decades of Data

After the full search and screening process, four trials met all inclusion criteria and were incorporated into the meta-analysis. These studies were published across a 22-year span, from 2003 to 2025 — a timeline that itself reflects how slowly evidence in this particular niche has accumulated. Three of the four trials examined candesartan; the fourth evaluated telmisartan, making it the only other ARB with trial-level evidence for migraine prevention.

Together, the four studies enrolled a combined total of 659 participants. All four reported outcomes for both migraine days and responder rates. Three of the four also reported data on headache days more broadly — a slightly different measure that captures pain days even when a headache does not meet the full clinical criteria for a migraine attack.

The Results: Meaningful Reductions and Stronger Response Rates

The combined effect size for migraine days was a reduction of 1.00 day per month compared to placebo (95% confidence interval: -1.51 to -0.49, p<0.001). For headache days, the reduction was slightly larger: 1.21 days per month (95% CI: -1.62 to -0.81, p<0.001). Both results were statistically highly significant, meaning the probability that these findings occurred by chance is extremely small.

The responder rate analysis — arguably the most clinically meaningful outcome — produced an odds ratio of 2.68 (95% CI: 1.91 to 3.78, p<0.001). In practical terms, this means someone taking an ARB was nearly three times more likely to see their migraine frequency cut in half than someone taking a placebo. Halving migraine frequency is the widely accepted threshold in clinical research for defining a clinically meaningful treatment response, and it is the benchmark used by regulatory agencies when evaluating preventive therapies.

Importantly, the heterogeneity between studies was categorized as 'might not be important' — a reassuring sign that the individual trials were measuring consistent effects rather than wildly different phenomena across different populations or study designs. No serious risk of bias was identified across the included trials.

How the Evidence Was Graded

Using the GRADEpro framework, the researchers rated the certainty of evidence as low for migraine days, moderate for responder rates, and high for headache days. The lower rating for migraine days likely reflects the smaller number of individual studies contributing to that specific analysis and the inherent variability in how migraine is diagnosed and counted across different clinical settings.

Having high-certainty evidence for headache days is notable. High certainty in GRADE terminology means further research is very unlikely to change the overall direction or magnitude of the finding. That is a relatively rare designation in the migraine prevention literature, where many established treatments were adopted into guidelines based on moderate or even low certainty evidence.

Candesartan's Long Shadow Over the Evidence Base

Three of the four included trials specifically investigated candesartan, which means the meta-analysis's conclusions are driven primarily by evidence for this one drug within the ARB class. Candesartan's presence in the migraine literature dates back to a landmark Norwegian study in 2003, which was the first randomized controlled trial to formally test an ARB in migraine prevention. That study generated significant interest but was not immediately followed by the large-scale replication studies that typically move a drug into guideline recommendations.

Over the subsequent two decades, additional small trials emerged, each individually underpowered to make definitive claims. The new meta-analysis effectively does what those individual trials could not: it treats their combined data as a single body of evidence, producing confidence intervals that are meaningfully narrow and effect sizes that hold up across the GRADE evaluation.

Telmisartan, represented by the fourth trial, contributes to the overall ARB picture but cannot yet stand alone as a studied drug in this indication. Whether telmisartan's specific pharmacological profile — it differs from candesartan in its receptor binding, half-life, and lipophilicity — translates to meaningfully different outcomes for migraine patients remains an open question.

Where ARBs Fit in the Existing Migraine Prevention Landscape

Migraine prevention — also called prophylactic or preventive treatment — is distinct from acute treatment, which aims to stop or shorten an attack that has already begun. Preventive therapies are taken daily, often for months or years, and their goal is to reduce how often attacks happen, how severe they are, and how long they last.

The current roster of preventive medications approved or widely recommended for migraine includes beta-blockers (such as propranolol and metoprolol), tricyclic antidepressants (such as amitriptyline), anticonvulsants (valproate and topiramate), and, in recent years, injectable CGRP-targeting antibodies such as erenumab, fremanezumab, and galcanezumab. Each class carries its own benefit-risk profile, tolerance considerations, and cost implications.

ARBs occupy an unusual position in this landscape. They are already widely prescribed for cardiovascular conditions, they have a well-characterized long-term safety profile, they are available as generics at low cost in most countries, and they are generally well tolerated — particularly in comparison to anticonvulsants, which carry risks of cognitive side effects and, in the case of valproate, serious risks for people of childbearing potential.

For the sizable population of migraine patients who also live with high blood pressure — a combination that is not uncommon, given the cardiovascular associations of migraine — an ARB could theoretically address both conditions simultaneously. That kind of 'dual benefit' treatment strategy is an appealing option in chronic disease management.

The Guideline Gap: Why Isn't This Drug Already Recommended More Widely?

The discrepancy between clinical practice — where many neurologists already use candesartan off-label for migraine prevention — and formal guideline recommendations is a familiar tension in medicine. Guidelines necessarily lag behind practice because they require a threshold of accumulated evidence before an official endorsement can be made.

The researchers behind this meta-analysis are direct about the implication of their findings: the evidence now available, including the high-certainty rating for headache days and the moderate-certainty rating for responder rates, meets or approaches the standards used to support other guideline-listed preventive therapies. They explicitly call for a reconsideration of ARBs' position in international guidelines.

Different countries and professional societies draw the line in different places. The American Headache Society, the European Headache Federation, and the International Headache Society each maintain their own guidelines, with slightly different criteria for what counts as adequate evidence. Whether this meta-analysis is enough to move the needle in one or all of these systems remains to be determined — but its pre-registered, dual-reviewer design and transparent GRADE ratings give it a methodological credibility that guideline committees typically value.

What This Doesn't Tell Us

Questions the Research Leaves Open

Several important scientific questions remain unanswered by this body of evidence. First, the mechanism through which ARBs reduce migraine frequency is not fully established. Multiple hypotheses exist — modulation of nociceptive processing (how the brain processes pain), direct effects on cerebral blood vessel tone, or anti-inflammatory actions on neurological tissue — but the relative contribution of each pathway is unclear.

Second, researchers do not yet know whether certain migraine subtypes respond better to ARBs than others. Migraine with aura, vestibular migraine, and chronic migraine may have different underlying neurobiological profiles that could make them more or less responsive to this class of drugs. Targeted trials or retrospective analyses stratified by subtype could illuminate this question.

Third, the question of optimal dosing — which dose of candesartan is most effective, and what dose adjustments might be needed for migraine prevention versus cardiovascular indications — has not been systematically resolved across these trials.

Fourth, the relationship between a patient's baseline blood pressure and their migraine response to ARBs is entirely uninvestigated in this dataset. It is plausible that the mechanism of benefit differs in hypertensive patients versus those with normal blood pressure, and that dosing approaches might need to differ accordingly.

Larger, adequately powered randomized controlled trials with longer follow-up periods — ideally comparing candesartan head-to-head with established first-line options — would significantly strengthen the evidence and accelerate any guideline reconsideration.

What This Means for People Living With Migraine

For the roughly one billion people worldwide estimated to live with migraine, the search for effective preventive treatment is a daily and often frustrating reality. Many patients cycle through multiple drug classes before finding one that works — and a significant proportion never achieve adequate control with available options. Expanding the evidence-based menu of preventive drugs matters because individual responses to migraine medications vary widely and unpredictably.

For patients who have not responded well to beta-blockers, who cannot tolerate the cognitive side effects of anticonvulsants, or for whom CGRP-targeting biologics are unavailable or unaffordable, candesartan represents a low-cost, established, and now more robustly evidenced option that could merit a trial. For patients already managing hypertension with an ARB, there may be an underappreciated co-benefit being delivered — or a case to be made for switching to candesartan specifically if migraine prevention is also a priority.

What to Discuss With Your Doctor

If you live with episodic migraine and are exploring or reconsidering your prevention options, this research provides a useful basis for a conversation with your neurologist or headache specialist. Not everyone is a candidate for ARBs — people with certain kidney conditions, women who are pregnant or planning to become pregnant, and those already on specific blood pressure medications may face contraindications. But for many patients, it is a question worth raising.

A Case for Reconsidering Where the Evidence Already Stands

One of the quiet arguments this meta-analysis makes is not just about what the research found, but about what it reveals regarding how evidence gets weighted in medicine. Candesartan has been used in clinical practice for migraine prevention for more than two decades. Individual trials have consistently pointed in the same direction. The new systematic review and meta-analysis brings that diffuse signal into focus, organizing the evidence in the structured format that guideline committees require.

The high GRADE certainty rating for headache days — meaning the research community is very confident in that particular result — is the kind of benchmark that shifts conversations in guideline development rooms. Whether this meta-analysis alone is sufficient to trigger guideline revisions, or whether it will serve as the catalyst for a new generation of larger dedicated trials, is the question that follows naturally from its publication.

For patients and clinicians alike, the practical takeaway is clear: the evidence behind ARBs for migraine prevention is now more robust than the absence of guideline endorsement might suggest. A drug class that has long been used at the margins of neurological practice now has a more solid empirical foundation to stand on — and that foundation deserves wider attention.